User login
Key clinical point: Adding ovarian function suppression (OFS) to adjuvant tamoxifen reduced the risk for recurrence in premenopausal patients with hormone receptor-positive (HR+) breast cancer (BC).
Major finding: Compared with tamoxifen alone, tamoxifen+OFS significantly improved the 12-year disease-free survival (hazard ratio [HR] 0.82; P = .03), with the improvement being greater with exemestane+OFS (HR 0.69; 95% CI 0.57-0.83).
Study details: Findings are from the SOFT trial including 3047 premenopausal women with HR+ BC who were randomly assigned to receive 5 years of adjuvant tamoxifen, tamoxifen+OFS, or exemestane+OFS.
Disclosures: This study was supported by Breast Cancer Trials Australia and New Zealand and other sources. The authors declared serving as consultants, advisors, or on speaker’s bureaus or receiving honoraria, research funding, or travel and accommodation expenses from several sources.
Source: Francis PA et al. Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT. J Clin Oncol. 2022 (Dec 9). Doi: 10.1200/JCO.22.01065
Key clinical point: Adding ovarian function suppression (OFS) to adjuvant tamoxifen reduced the risk for recurrence in premenopausal patients with hormone receptor-positive (HR+) breast cancer (BC).
Major finding: Compared with tamoxifen alone, tamoxifen+OFS significantly improved the 12-year disease-free survival (hazard ratio [HR] 0.82; P = .03), with the improvement being greater with exemestane+OFS (HR 0.69; 95% CI 0.57-0.83).
Study details: Findings are from the SOFT trial including 3047 premenopausal women with HR+ BC who were randomly assigned to receive 5 years of adjuvant tamoxifen, tamoxifen+OFS, or exemestane+OFS.
Disclosures: This study was supported by Breast Cancer Trials Australia and New Zealand and other sources. The authors declared serving as consultants, advisors, or on speaker’s bureaus or receiving honoraria, research funding, or travel and accommodation expenses from several sources.
Source: Francis PA et al. Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT. J Clin Oncol. 2022 (Dec 9). Doi: 10.1200/JCO.22.01065
Key clinical point: Adding ovarian function suppression (OFS) to adjuvant tamoxifen reduced the risk for recurrence in premenopausal patients with hormone receptor-positive (HR+) breast cancer (BC).
Major finding: Compared with tamoxifen alone, tamoxifen+OFS significantly improved the 12-year disease-free survival (hazard ratio [HR] 0.82; P = .03), with the improvement being greater with exemestane+OFS (HR 0.69; 95% CI 0.57-0.83).
Study details: Findings are from the SOFT trial including 3047 premenopausal women with HR+ BC who were randomly assigned to receive 5 years of adjuvant tamoxifen, tamoxifen+OFS, or exemestane+OFS.
Disclosures: This study was supported by Breast Cancer Trials Australia and New Zealand and other sources. The authors declared serving as consultants, advisors, or on speaker’s bureaus or receiving honoraria, research funding, or travel and accommodation expenses from several sources.
Source: Francis PA et al. Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT. J Clin Oncol. 2022 (Dec 9). Doi: 10.1200/JCO.22.01065